Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.48 ^USD	-3.33%		-4.13%	-84.16%

Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 04:31 pm EST

Tenax Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 1.97 million compared to USD 2.92 million a year ago. Basic loss per share from continuing operations was USD 6.4 compared to USD 177.6 a year ago.
For the nine months, net loss was USD 4.49 million compared to USD 8.5 million a year ago. Basic loss per share from continuing operations was USD 19.2 compared to USD 531.2 a year ago.

Latest news about Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics Secures Global Rights for Levosimendan	Feb. 20	MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	Feb. 20	CI
Top Midday Decliners	Feb. 08	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	Feb. 08	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	Feb. 08	MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	Feb. 08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	Feb. 07	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06	MT
Sector Update: Health Care	Feb. 06	MT
Top Midday Gainers	Feb. 06	MT
Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer	Jan. 12	CI
Tenax Therapeutics, Inc. Announces Chief Financial Officer Changes	Jan. 12	CI
Tenax Therapeutics to Implement 1-for-80 Reverse Stock Split	Dec. 29	MT
Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board	Nov. 17	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	Nov. 13	MT
Sector Update: Health Care	Nov. 13	MT
Top Midday Gainers	Nov. 13	MT
Tenax Therapeutics Shares Double Premarket After FDA Clears IND for TNX-103	Nov. 13	DJ
Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure	Nov. 13	CI
Tenax Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	23-07-19	CI
Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application	23-05-31	CI

Chart Tenax Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Companyâs other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.48 USD

Average target price

32.5 USD

Spread / Average Target

+833.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TENAX THERAPEUTICS, INC.	-84.16%	6.81M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research